FREDERICK, Md., July 26, 2024 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report results for the second quarter ended June 30, 2024, after the close of the financial markets on Thursday, August 1, 2024, and will hold a conference […]
Category Archives: Pr Newswire
Pr Newswire
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at 8:30am ET on Monday July 29, 2024
27
Jul
Jul
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders will host an investor webcast on Monday, July 29, 2024 at 8:30a.m. ET to discuss the clinical efficacy, safety and biomarker findings from the Phase 2 COG0201 “SHINE” […]
Pr Newswire
vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold
27
Jul
Jul
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes […]
Pr Newswire
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
27
Jul
Jul
Company to host conference call on Monday, July 29 at 8:30 a.m. ET NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density […]
27
Jul
Jul
Publication of the 2024 Interim Financial Report Paris, France (July 26, 2024 – 6:30 pm) – The Board of Directors of EssilorLuxottica met on July 25, 2024 to approve the condensed consolidated interim financial statements for the six-month period ended June 30, 2024. EssilorLuxottica’s 2024 Interim Financial Report has been published today. The Interim Financial […]
MUMBAI, India, July 26, 2024 /PRNewswire/ — InfoComm India, India’s foremost professional audiovisual (Pro AV) exhibition, is set to return to Mumbai from 3-5 September 2024 at the Jio World Convention Centre (JWCC). This year, InfoComm India 2024 expands beyond Pavilions 1 to 3 at JWCC, incorporating Jasmine Hall (at Level 3) for an even […]
SINGAPORE, July 27, 2024 /PRNewswire/ — Chenghe Acquisition II Co. (the “Company“) today announced that, commencing on July 29, 2024, holders of the units (the “Units“) sold in the Company’s initial public offering may elect to separately trade the Company’s Class A Ordinary Shares (the “Shares“) and warrants (the “Warrants“) included in the Units. The […]
PALO ALTO, Calif., July 27, 2024 /PRNewswire/ — Mega Matrix Corp. (“MPU” or the “Company”) (NYSE American: MPU), today announced that FlexTV, its short drama streaming platform, surged into No.8. in the App Store Entertainment Apps (Free Apps, Japan) as of July 26, 2024. FlexTV continues to excel in the Asian market! Following its 2nd […]
XINING, China, July 27, 2024 /PRNewswire/ — vivo today held the 2024 vivo Imaging Conference in Xining, China, where it showcased vivo’s latest advancements in imaging technologies. The company presented its progressive strategies surrounding three new trends in mobile imaging: imaging security, 3D imaging/XR and health imaging. In addition, the results of the VISION+ Mobile PhotoAwards […]
The positive CHMP opinion is based on results from the Phase II PHAROS trial,[1] which demonstrated an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients. The safety profile is consistent with that observed in the approved metastatic melanoma indication[1] The European Commission decision for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) is expected […]